207 related articles for article (PubMed ID: 25164908)
1. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Moran T; Wei J; Cobo M; Qian X; Domine M; Zou Z; Bover I; Wang L; Provencio M; Yu L; Chaib I; You C; Massuti B; Song Y; Vergnenegre A; Lu H; Lopez-Vivanco G; Hu W; Robinet G; Yan J; Insa A; Xu X; Majem M; Chen X; de Las Peñas R; Karachaliou N; Sala MA; Wu Q; Isla D; Zhou Y; Baize N; Zhang F; Garde J; Germonpre P; Rauh S; ALHusaini H; Sanchez-Ronco M; Drozdowskyj A; Sanchez JJ; Camps C; Liu B; Rosell R; ; Colinet B; De Grève J; Germonpré P; Chen H; Chen X; Du J; Gao Y; Hu J; Hu W; Kong W; Li L; Li R; Li X; Liu B; Liu J; Lu H; Qian X; Ren W; Song Y; Wang L; Wei J; Wen L; Wu Q; Xiao X; Xu X; Yan J; Yang J; Yang M; Yang Y; Yin J; You C; Yu L; Yue X; Zhang F; Zhang J; Zhou Y; Zhu L; Zou Z; Baize N; Bombaron P; Chouaid C; Dansin E; Fournel P; Fraboulet G; Gervais R; Hominal S; Kahlout S; Lecaer H; Lena H; LeTreut J; Locher C; Molinier O; Monnet I; Oliviero G; Robinet G; Schoot R; Thomas P; Vergnènegre A; Berchem G; Rauh S; Al Husaini H; Aparisi F; Arriola E; Ballesteros I; Barneto I; Bernabé R; Blasco A; Bosch-Barrera J; Bover I; Calvo de Juan V; Camps C; Carcereny E; Catot S; Cobo M; De Las Peñas R; Dómine M; Felip E; García-Campelo MR; García-Girón C; García-Gómez R; Garcia-Sevila R; Garde J; Gasco A; Gil J; González-Larriba JL; Hernando-Polo S; Jantus E; Insa A; Isla D; Jiménez B; Lianes P; López-López R; López-Martín A; López-Vivanco G; Macias JA; Majem M; Marti-Ciriquian JL; Massuti B; Montoyo R; Morales-Espinosa D; Morán T; Moreno MA; Pallares C; Parera M; Pérez-Carrión R; Porta R; Provencio M; Reguart N; Rosell R; Rosillo F; Sala MA; Sanchez JM; Sullivan I; Terrasa J; Trigo JM; Valdivia J; Viñolas N; Viteri S; Botia-Castillo M; Mate JL; Perez-Cano M; Ramirez JL; Sanchez-Rodriguez B; Taron M; Tierno-Garcia M; Mijangos E; Ocaña J; Pereira E; Shao J; Sun X; O'Brate R
Ann Oncol; 2014 Nov; 25(11):2147-2155. PubMed ID: 25164908
[TBL] [Abstract][Full Text] [Related]
2. [Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Wei J; Qian XP; Zou ZY; Wang LF; Yu LX; You CW; Song Y; Lu HY; Hu WJ; Yan J; Xu XX; Chen XF; Li XY; Wu QF; Zhou Y; Zhang FL; Liu BR
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):868-873. PubMed ID: 27998448
[No Abstract] [Full Text] [Related]
3. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Rosell R; Perez-Roca L; Sanchez JJ; Cobo M; Moran T; Chaib I; Provencio M; Domine M; Sala MA; Jimenez U; Diz P; Barneto I; Macias JA; de Las Peñas R; Catot S; Isla D; Sanchez JM; Ibeas R; Lopez-Vivanco G; Oramas J; Mendez P; Reguart N; Blanco R; Taron M
PLoS One; 2009; 4(5):e5133. PubMed ID: 19415121
[TBL] [Abstract][Full Text] [Related]
4. Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).
Wei J; Moran T; Zou Z; Qian X; Wang L; Camps C; Hu W; Chaib I; Sanchez B; Xu L; Karachaliou N; Sanchez-Ronco M; Liu B; Rosell R
Transl Lung Cancer Res; 2013 Jun; 2(3):180-8. PubMed ID: 25806231
[TBL] [Abstract][Full Text] [Related]
5. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
Karachaliou N; Bracht JWP; Fernandez Bruno M; Drozdowskyj A; Gimenez Capitan A; Moran T; Carcereny E; Cobo M; Domine M; Chaib I; Ramirez JL; Camps C; Provencio M; Vergnenegre A; Lopez-Vivanco G; Majem M; Massuti B; Rosell R
J Thorac Oncol; 2019 Feb; 14(2):304-310. PubMed ID: 30472259
[TBL] [Abstract][Full Text] [Related]
6. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
7. Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Wang LR; He LJ; Wang Y; Li YY; Lou Y; Zhang GB; Li Y; Chen J
Cancer Chemother Pharmacol; 2015 Jul; 76(1):163-70. PubMed ID: 26003539
[TBL] [Abstract][Full Text] [Related]
8. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
[TBL] [Abstract][Full Text] [Related]
9. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
Rosell R; Tonato M; Sandler A
Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
[TBL] [Abstract][Full Text] [Related]
11. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
17. Genetic testing for chemotherapy in non-small cell lung cancer.
Rosell R; Taron M; Alberola V; Massuti B; Felip E
Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
[TBL] [Abstract][Full Text] [Related]
18. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Katakami N; Takiguchi Y; Yoshimori K; Isobe H; Bessho A; Yoshimura A; Niitani H
J Thorac Oncol; 2006 Jun; 1(5):447-53. PubMed ID: 17409898
[TBL] [Abstract][Full Text] [Related]
20. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
